Figure S2 from Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2− Breast Cancer

Key Points

• Secondary resistance to endocrine therapy was observed in the SNF3 subtype of breast cancer, signaling a need for tailored approaches.
• The study highlights precision treatment implications for HR+/HER2- breast cancer patients, suggesting a shift from one-size-fits-all strategies.
• Assessment of treatment response demonstrated notable differences among subtypes, indicating varying therapeutic needs and potential outcomes.
• This exploration into subtype-directed precision treatment calls for further research to optimize therapeutic interventions in breast cancer care.